Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...

The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...

The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...

Danes spent a record 38.5 billion DKK in retail during December 2023, marking a 3.2% increase compared to the previous year, according to Statistics Denmark. The holiday season, traditionally the peak ...

Ninety percent of products from online marketplaces have failed to meet EU safety standards, according to a new investigation by the Danish Safety Technology Authority (Sikkerhedsstyrelsen). The ...